Micheál Carrigy has met with Biogen which manufactures the drug for Friedreich's Ataxia.
There's a call on the provider of a drug for Friedreich's ataxia to consider a compassionate access scheme.
Negotiations are currently underway between the HSE and Biogen regarding the cost of supplying Skyclarys.
However, the HSE has upheld a recommendation not to reimburse the drug, as it would cost around 280 thousand euro per patient per year.
Fine Gael's Micheál Carrigy met with Biogen, and is recommending an alternative step:
Missing Westmeath Teenager Found Safe And Well
Uisce Éireann Faces €8.2m Charge For Shannon Pipeline In Offaly
Arts Council Awards Over €17m In Funding To 220 Recipients Nationwide
Regional Health Forum Chair ‘Shocked’ As Spending Powers Are Curbed
Westmeath Council Approves 74 New Homes
Westmeath Landlord Ordered To Pay €15k In Damages For "Egregious" Actions
Iarnród Éireann Adding Extra Trains For National Ploughing Championships
Ryanair Boss Compares Rival Airlines To Rapists Over High Fares